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Background:Ovarian cancer is the leading cause of death among cancers of the female genital tract, with poor outcomes despite
chemotherapy. There was a persistent socioeconomic gradient in 1-year survival in England and Wales for more than 3 decades
(1971–2001). Inequalities in 5-year survival persisted for more than 20 years but have been smaller for women diagnosed around
2000. We explored one possible explanation.
Methods: We analysed data on 1406 women diagnosed with ovarian cancer during 1991–1998 and recruited to one of two
randomised clinical trials. In the second International Collaborative Ovarian Neoplasm (ICON2) trial, women diagnosed between
1991 and 1996 were randomised to receive either the three-drug combination cyclophosphamide, doxorubicin and cisplatin (CAP)
or single-agent carboplatin given at optimal dose. In the ICON3 trial, women diagnosed during 1995–1998 were randomised to
receive either the same treatments as ICON2, or paclitaxel plus carboplatin. Relative survival at 1, 5 and 10 years was estimated for
women in five categories of socioeconomic deprivation. The excess hazard of death over and above background mortality was
estimated by fitting multivariable regression models with Poisson error structure and a dedicated link function in a generalised
linear model framework, adjusting for the duration of follow-up and the confounding effects of age, Federation of Gynecology
and Obstetrics (FIGO) stage and calendar period.
Results: Unlike women with ovarian cancer in the general population, no statistically significant socioeconomic gradient was seen
for women with ovarian cancer treated in the two randomised controlled trials. The deprivation gap in 1-year relative survival in the
general population was statistically significant at  6.7% (95% CI ( 8.1,  5.3)), compared with  3.6% (95% CI ( 10.4, þ 3.2)) in
the trial population.
Conclusions: Although ovarian cancer survival is significantly lower among poor women than rich women in England and Wales,
there was no evidence of an association between socioeconomic deprivation and survival among women with ovarian cancer who
were treated and followed up consistently in two well-conducted randomised controlled trials. We conclude that the persistent
socioeconomic gradient in survival among women with ovarian cancer, at least for 1-year survival, may be due to differences in
access to treatment and standards of care.
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Socioeconomic disparities in survival are observed for many adult
cancers in England and Wales (Coleman et al, 2004; Rachet et al,
2008) and in other parts of the world (Woods et al, 2006; Jeffreys
et al, 2009). For ovarian cancer in England and Wales, throughout
the 31-year period 1971–2001, 1-year survival in the most deprived
group of women was 7–9% lower than in the most affluent group
(Coleman et al, 1999; Cooper et al, 2008). For 5-year survival, this
‘deprivation gap’ was 2–3% for women diagnosed up to 1990;
however, it then declined, and no deprivation gap in 5-year
survival was observed for women diagnosed around 2000.
Socioeconomic disparities in ovarian cancer survival are only
partially explained by differences in the extent of disease at
diagnosis and differences in treatment (Woods et al, 2006). In the
United States of America, ovarian cancer survival is substantially
lower in Blacks than Whites (Barnholtz-Sloan et al, 2002).
Differences in ovarian cancer survival may be explained by
differences in tumour biology and morphology, delay in diagnosis,
the quality of the staging procedures or differences in treatment
(Maringe et al, 2012).
One way to assess whether socioeconomic differences in survival
are related to treatment is to measure the deprivation gap in a
setting that is not directly affected by other aspects of the health-
care system (Nur et al, 2008, 2012). Patients recruited to clinical
trials are randomly assigned to specific treatment regimes
regardless of their socioeconomic status, or indeed of any other
potentially confounding variable. Close adherence to trial protocol
ensures equality of access to and compliance with treatment among
all socioeconomic groups. The impact of age and stage at diagnosis
on socioeconomic differentials can be quantified in the analysis;
however, only a small proportion of women with ovarian cancer
are recruited to clinical trials. By contrast, population-based studies
are very large because they include all patients, thus providing a
public health perspective on socioeconomic inequalities in out-
come; however, data on stage and treatment are rarely available for
all patients (Walters et al, 2013). This makes it more difficult to
control for early diagnosis, stage and treatment when quantifying
socioeconomic differences in survival in the general population.
The objective of this study was to investigate socioeconomic
differences in ovarian cancer survival among women recruited to
randomised trials and to compare these differences with those
observed among women with ovarian cancer in the general
population. If the ‘deprivation gap’ in survival in the general
population also arises in a trial, then it is more likely to be because
of biological or environmental factors than to differences in
treatment. If, on the other hand, a socioeconomic survival gradient
is not observed in a clinical trial, after adjustment for known
prognostic factors, then the deprivation gap in survival in the
general population is more likely to be because of differences in
treatment, since that is the one factor that is reliably and equally
accessible to all socioeconomic groups within a randomised trial.
PATIENTS AND METHODS
Study population. This study used data on women from England
and Wales recruited to two international ovarian cancer trials,
linking data from the MRC Trials Unit, the National Cancer
Registry and other sources.
As part of the International Collaborative Ovarian Neoplasm
(ICON) studies, the Medical Research Council (MRC) Cancer Trial
Office in Cambridge, UK (now the MRC Clinical Trials Unit,
London) participated in two trials, ICON2 and ICON3, which
compared the outcome from various chemotherapy treatments
after definitive local surgery. The main eligibility criterion was that
the woman was assessed by the clinician as requiring chemother-
apy and being fit to receive it. The trials included women in both
early and advanced stages of disease. The women’s socioeconomic
status was not recorded at recruitment.
ICON2 recruited women between January 1991 and July 1996
and compared two internationally standard regimens in a 1 : 1
ratio: the three-drug combination of cyclophosphamide, doxo-
rubicin and cisplatin (CAP) against single-agent carboplatin given
at an optimal dose. For ICON3, women were recruited between
February 1995 and October 1998 and randomised 2 : 1 to a choice
of the ICON2 treatments, or randomisation within the ICON2
protocol, or to paclitaxel plus carboplatin.
Randomisation was performed by straight minimisation,
stratifying by (i) centre, (ii) disease stage (using the International
Federation of Gynecology and Obstetrics (FIGO) stage) and
(iii) residual bulk of disease, plus for ICON3 only (iv) time since
surgery and (v) choice of control regimen. This method ensures
balance between treatment groups for the specified factors (Pocock
and Simon, 1975). Both trials aimed to compare progression-free
and overall survival between the treatment regimens. Detailed
descriptions of ICON2 (Parmar et al, 2002) and ICON3 (Parmar
et al, 1998) have been published. The results showed no evidence of
differences in survival between the various treatment regimens
(ICON2: hazard ratio 1.00, 95% CI 0.86–1.16, P-value 0.98;
ICON3: hazard ratio 0.98, 95% CI 0.87–1.10, P-value 0.74). For the
analyses reported here, socioeconomic differences in survival
among the women recruited to each trial were therefore analysed
without reference to the various treatment protocols. The key is
that all the women in the trials received treatments which, we now
know, were either identical, if they were in the same arm of the
trial, or equivalent with respect to outcome, if in different arms.
The MRC Clinical Trials Unit provided information on the date
of birth, the tumour, FIGO stage, date of randomisation, type of
treatment and the outcome for all women recruited to ICON2 and
ICON3. For women resident in England and Wales at diagnosis,
the Office for National Statistics (ONS) provided information on
vital status at 31 December 2007 – the last day of follow-up for this
study – and the date of death for women who had died, by linkage
between the National Cancer Registry and the National Health
Service Central Register (NHSCR).
An ecological deprivation score was assigned to each woman,
based on the characteristics of the Lower Super Output Area
(LSOA) in which she was resident at diagnosis, and the year of
diagnosis. The 34 378 LSOAs in England and Wales are small areas
(mean population 1500) covering the entire country and for which
detailed data on a wide range of routinely collected variables, such
as income, employment and housing, are available to characterise
the level of deprivation of the residents. The Carstairs score
(Carstairs, 1995), derived from the 1991 Census, was used for
women diagnosed up to 1995. For those diagnosed in 1996 or later,
the income domain score of the Indices of Multiple Deprivation
(IMD2004; Neighbourhood Renewal Unit, 2004) was used. LSOA
deprivation scores were grouped into five categories, from the most
affluent (1) to the most deprived (5), based on quintiles of the
national distribution. Women with ovarian cancer were assigned to
the deprivation category of their LSOA of residence, using their
postcode and a combined historic file of over 2 million unique
postcodes, linked to geographic area codes for each calendar year.
For a given geographic unit in England and Wales in a given
calendar period, the deprivation gap in survival is similar for all
measures of deprivation (Woods et al, 2005).
A total of 1406 women recorded in the trial databases as
resident in England or Wales were considered for analysis: 272 in
ICON2 and 1134 in ICON3. Of these, 1290 (92%; 242 in ICON2,
1048 in ICON3) were analysed after the following exclusions
(Figure 1): (i) 73 women who could not be linked to a cancer
registration record and thus to information on their vital status;
(ii) 2 women with incomplete information on deprivation; (iii) 41
women with either no date of diagnosis (18), unknown vital status
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(2), synchronous tumours (3), metastasis to the ovary from another
primary site (12) or not recorded as resident in England or Wales
in the National Cancer Registry (6).
This research was approved by the Ethics Committee of the
London School of Hygiene and Tropical Medicine. Appropriate
ethical approvals were originally given to both ICON2 and ICON3
protocols, and approval to flag the patients for their vital status in
the NHSCR was obtained from ONS.
Statistical analyses. Survival time was measured in days between
the exact date of randomisation during the period 1991–1998 and
the date of last vital status (the earlier of the date of death and 31
December 2007), and recorded in years (days/365.25).
Cumulative all-cause and relative survival up to 5 years after
randomisation was estimated for each deprivation category.
Survival probabilities were estimated at 3-month intervals for the
first 6 months, then 6-month intervals up to 2 years and at annual
intervals thereafter. Relative survival was estimated with the
maximum likelihood approach for individual records (Este`ve
et al, 1990), using the strel program (Cancer Research UK Cancer
Survival Group, 2010) in Stata version 10 (StataCorp, 2006; College
Station, TX, USA).
Relative survival (Ederer et al, 1961) may be interpreted as the
survival from cancer after correction for other causes of death. It is
defined as the ratio of the survival observed in the cancer patients
and the survival that would have been expected had they been
subjected only to the mortality rates observed in the general
population (background mortality; Coleman et al, 1999).
Background mortality was taken from national life
tables (Cancer Research UK Cancer Survival Group, 2004)
incorporating all-cause death rates for women in England and
Wales by single year of age (up to 99 years), single calendar year
and deprivation category. Life tables were constructed from the
numbers of deaths and the census populations by age and LSOA
for 1991 and 2001, and smoothed using a Poisson regression model
with spline functions. Intercensal life tables were interpolated
linearly. Life tables for 2006 and 2007 could not be constructed
because the relevant data (deaths during 2007–2008) were
unavailable, so life tables for 2005 were used for these years
without extrapolation. Survival gradients were estimated with
variance-weighted linear regression (Grizzle et al, 1969) across all
five categories of deprivation. The deprivation gap was taken as the
absolute difference between the fitted relative survival estimates for
the most affluent and the most deprived groups of women. A
negative value is used to indicate that survival was lower for the
most deprived group than the most affluent group.
We compared survival in the trial population with survival for
all women diagnosed with an invasive primary ovarian malignancy
in England and Wales during the same calendar period as the trial
recruitment, also followed up to 31 December 2007. The
deprivation gap was estimated in an identical manner for women
in the trials and, separately, for all women registered with ovarian
cancer in England and Wales during 1991–1998.
To estimate variations in survival due to deprivation, multi-
variable regression models were fitted in a Generalised Linear
Model framework, with Poisson error structure and a dedicated
link function (Dickman et al, 2004), adjusting for duration of
follow-up, age, FIGO stage and period of diagnosis. The excess
hazard of death over and above the background mortality in each
deprivation category was modelled up to 5 years after randomisa-
tion. The excess hazard was assumed to be constant within each of
a series of pre-specified time intervals since randomisation (Este`ve
et al, 1990): 3-month intervals for the first 6 months, 6-month
intervals up to 2 years and annual intervals thereafter. Estimation
was based on exact survival times using grouped data (Dickman
et al, 2004).
The initial model included the main effects of follow-up time
and deprivation. Age at randomisation (under 55, 55–65, over 65
years), calendar period at randomisation (1991–1995, 1996–1999)
and FIGO stage (I–IV) were successively included in the model.
For each variable, time-dependent effects were tested separately by
the introduction of interactions with time. Interactions between
other factors were similarly tested. The likelihood ratio test (P-
value o0.05) was used to assess improvement in model fit by the
addition of other variables and interaction terms. Deviance
statistics (McCullagh and Nelder, 1999) and residual plots were
used as measures of goodness of fit.
Excess hazard ratios (EHRs), with their 95% confidence
intervals, are presented as the ratio of the excess hazard of death
within 5 years of diagnosis in a given deprivation category relative
to the most affluent category (reference group), after controlling
for other factors included in the model.
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Figure 1. The study population.
No socioeconomic inequalities in ovarian cancer survival BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.303 591
RESULTS
Women recruited to the ICON trials were evenly distributed across
the five deprivation categories (18–21%; Table 1), very similar to
the pattern for all women diagnosed with ovarian cancer in
England and Wales during 1991–1998 (18–21%). Most women in
the trials were under the age of 65 years, with a median age of 58
years, compared with a median of 65 years for all women with
ovarian cancer in England and Wales. Almost two-thirds of
women (63%) were recruited with stage III disease, with little
variation between socioeconomic groups (Table 1).
By the end of the follow-up, some 10–16 years after recruitment,
1086 (84%) of the women had died; the remaining 204 women
were censored from the analysis at study closure on 31 December
2007.
For women in the trials, 1-year survival was 77–78% in the three
more affluent categories and 74–75% for the two most deprived
groups (Table 2, Figure 2). One-year survival was 12–17% (mean
14.3%) higher than for women in the same deprivation category in
the general population during the same period, regardless of
disease stage or treatment plan. For women in the trial, the fitted
deprivation gap in 1-year survival was negative at  4% (95% CI
( 10, þ 3)), whereas the deprivation gap in the general
population was wider, and statistically significant:  7% (95% CI
( 8,  5)).
Overall 5-year survival for women in the trials was 29.1% (95%
CI 26.5–31.6%) some 4% lower than for unselected women with
ovarian cancer in the general population during the same period
33.5% (33.0–34.0%; Table 2, Figure 2). There was no consistent
pattern by deprivation category, and the fitted deprivation gap was
 4% ( 12 to þ 3%). The deprivation gap in survival in the
general population was smaller:  1% ( 3 to 0%).
Ten-year survival was only 19.5% (17.2–21.9%) for women in
the trials, some 9% lower than for all women with ovarian cancer
in the general population (28.5%, 28.0–29.0%). There was no
strong evidence of a deprivation gradient in 10-year survival, either
among women in the trials (1.2%,  5.5 to þ 7.9%), or among
women with ovarian cancer in the general population (0%,  1.1
to þ 1.9%).
The socioeconomic gradient in the excess hazard of death
within 5 years of diagnosis was small (1.17; 95% CI 0.95–1.44;
P-value 0.391; Table 3).
The excess hazard was higher for women aged 55–65 and those
over 65 years at diagnosis than for women aged less than 55
(reference category; EHR 1.25, 95% CI 1.1–1.5 for both groups;
Table 3). The excess hazard was lower for women randomised
during 1996–1999 than for those who were randomised on average
about 5 years earlier, during 1991–1995 (EHR 0.85, 95% CI 0.74–
0.98): this represents a 15% reduction among patients diagnosed
over that 5-year period in the excess hazard of death within 5 years
of diagnosis. The excess hazard also shows a marked and
progressive increase across the four categories of FIGO stage at
diagnosis (up to 4.3-fold for FIGO stage IV). All three effects are to
be expected, and they largely explain even the modest deprivation
gradient in the overall excess hazard (Table 3). Interaction of
Table 1. Distribution (no. and %) of women recruited to ICON2 and ICON3 trials of ovarian cancer during 1991–1998 by deprivation category
Deprivation category
Affluent 2 3 4 Deprived All women
No. % No. % No. % No. % No. % No. %
Trial
ICON2 43 17.8 56 23.1 49 20.2 53 21.9 41 16.9 242 100.0
ICON3 230 21.9 188 17.9 223 21.3 212 20.2 195 18.6 1048 100.0
Treatment
ICON2: CAP 18 14.6 38 30.9 24 19.5 26 21.1 17 13.8 123 100.0
Carboplatin 25 21.0 18 15.1 25 21.0 27 22.7 24 20.2 119 100.0
ICON3: Control 149 21.4 130 18.7 146 20.9 146 20.9 126 18.1 697 100.0
Paclitaxel 81 23.1 58 16.5 77 21.9 66 18.8 69 19.7 351 100.0
Age (years)
o55 109 22.1 91 18.5 108 21.9 100 20.3 85 17.2 493 100.0
55–65 110 22.8 88 18.2 103 21.3 101 20.9 81 16.8 483 100.0
465 54 17.2 65 20.7 61 19.4 64 20.4 70 22.3 314 100.0
Period of randomisation
1991–1995 76 19.0 92 22.9 85 21.2 80 20.0 68 17.0 401 100
1996–1999 197 22.2 152 17.1 187 21.0 185 20.8 168 18.9 889 100
FIGO stage
Stage I 23 21.7 19 17.9 24 22.6 25 23.6 15 14.2 106 100
Stage II 37 24.3 34 22.4 39 25.7 21 13.8 21 13.8 152 100
Stage III 171 21.0 155 19.0 157 19.2 176 21.6 157 19.2 816 100
Stage IV 42 19.4 36 16.7 52 24.1 43 19.9 43 19.9 216 100
Total 273 21.2 244 18.9 272 21.1 265 20.5 236 18.3 1290 100.0
Abbreviations: CAP¼ cyclophosphamide, doxorubicin and cisplatin; FIGO¼ International Federation of Gynecology and Obstetrics; ICON¼ International Collaborative Ovarian Neoplasm.
Treatment arm, age group, calendar period and stage at diagnosis are shown.
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deprivation category with time since diagnosis was not statistically
significant (P-value 0.473), and none of the other interactions was
found to be significant.
DISCUSSION
The distribution of socioeconomic status among the women
recruited to these ovarian cancer trials in the 1990s was closely
similar to that seen among women with ovarian cancer in the
general population during the same period. This suggests that
recruitment to the trials was carried out without socioeconomic
bias. The socioeconomic status of the women was not known to the
trial investigators: it was established only for our study, many years
after closure of the trial, on the basis of each woman’s small area of
residence at diagnosis.
Misclassification of socioeconomic status by area of residence is
likely to be very minor because the areas used are very small
(N¼ 34 378, mean population 1500) and they were designed to be
fairly homogeneous for socioeconomic status. Since we used an
ecological measure, any bias in the socioeconomic gradient in
outcome arising from such misclassification would be towards the
null, both for the trial patients and the general population.
We found no strong evidence of a gradient in 1-year, 5-year or
10-year survival across five socioeconomic categories among
Table 2. Relative survival (%) at 1 and 5 years, by deprivation category, and fitted deprivation gap in survival
Women recruited to trials General population
No. of women No. of deaths Relative survival 95% CI Relative survival 95% CI
One year
Survival
Overall 1290 317 76.2 (73.8, 78.5) 62.0 (61.5, 62.5)
Deprivation
Affluent 273 64 77.2 (71.7, 81.8) 65.6 (64.5, 66.7)
2 244 56 77.9 (72.0, 82.7) 64.1 (63.0, 65.2)
3 272 64 77.0 (71.5, 81.6) 60.4 (59.3, 61.4)
4 265 68 75.0 (69.2, 79.8) 60.2 (59.1, 61.3)
Deprived 236 65 74.0 (67.8, 79.2) 59.4 (58.1, 60.5)
Deprivation
Gap 3.6 6.7a
95% CI (10.4, 3.2) ( 8.1, 5.3)
Five years
Survival
Overall 1290 932 29.1 (26.5, 31.6) 33.5 (33.0, 34.0)
Deprivation
Affluent 273 186 32.7 (27.1, 38.4) 34.6 (33.5, 35.7)
2 244 177 28.5 (22.8, 34.5) 33.7 (32.6, 34.8)
3 272 198 28.4 (23.0, 34.0) 32.6 (31.5, 33.7)
4 265 197 26.7 (21.4, 32.4) 33.3 (32.2, 34.4)
Deprived 236 174 28.7 (22.7, 34.8) 33.3 (32.1, 34.5)
Deprivation
Gap 4.2  1.3
95% CI (11.6, þ3.2) ( 2.7, þ0.2)
Ten years
Survival
Overall 1290 1065 19.5 (17.2, 21.9) 28.5 (28.0, 29.0)
Deprivation
Affluent 273 219 21.5 (16.6, 26.8) 29.1 (28.0, 30.2)
2 244 209 15.2 (10.8, 20.4) 28.0 (27.0, 29.1)
3 272 226 19.3 (14.6, 24.6) 27.5 (26.5, 28.6)
4 265 215 21.0 (16.0, 26.4) 28.9 (27.8, 30.0)
Deprived 236 196 19.9 (14.7, 25.8) 29.2 (28.0, 30.5)
Deprivation
Gap 1.2 0.4
95% CI (5.5, þ7.9) ( 1.1, þ1.9)
Abbreviations: CI¼ confidence interval; ICON¼ International Collaborative Ovarian Neoplasm. Women with ovarian cancer recruited to ICON2 and ICON3 trials during 1991–1998, and all
women diagnosed with ovarian cancer in the general population of England and Wales during the same period are shown.
aStatistically significant at 5%.
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women recruited to these two randomised trials of ovarian cancer
treatment in England and Wales in the 1990s. This was at a time
when a significant deprivation gap in 1-year ovarian cancer
survival existed in the general population. Further, there was no
statistically significant difference between rich and poor women in
the excess hazard of death within 5 years in the trials, either before
or after adjustment for age, calendar period and FIGO stage at
diagnosis.
By contrast, for women with ovarian cancer in the general
population, there was a significant deprivation gap in 1-year
survival throughout the period 1971–1999 (Coleman et al, 1999).
The absence of such a gradient among women recruited to
randomised trials during the 1990s suggests that the socioeconomic
differences in survival in the general population may be because of
inequity of access to or quality of treatment.
Stage at diagnosis was similar for women in each deprivation
category, and no deprivation gap in survival was observed in the
trial. As survival does vary with deprivation in the general
population, this suggests that deprived women in the general
population are generally diagnosed at a more advanced stage than
affluent women, and/or that there are socioeconomic differences in
access to optimal treatment (Kitchener, 2008). Some evidence
exists on stage: in a population-based audit in Scotland, the
proportion of FIGO stage III/IV tumours was higher among
women in the most deprived category than among those in the
least deprived (67.3% vs 58.2%); the proportion of women for
whom stage data were missing was also slightly higher (11.9% vs
7.9%; Brewster et al, 2001).
The deprivation gap in 5- and 10-year survival in the general
population was not statistically significant for women diagnosed
after 1990. This is consistent with the significant and persistent
deprivation gap (around 5%) in 1-year survival in England and
Wales, but not at 5 or 10 years, throughout the period 1986–1999
(Coleman et al, 1999). Most of the excess deaths associated with
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Figure 2. One- and five-year relative survival (%) by deprivation
category for women diagnosed with ovarian cancer during 1991–1998
in the ICON trials and in the general population of England andWales.
Table 3. Excess hazard ratios (EHR) of death within 5 years of diagnosis (with 95% confidence intervals) by deprivation category, before and after
adjustment for age, calendar period of randomisation and FIGO stage at diagnosis
Unadjusted
Adjusted for age and calendar period of
randomisation
Global
EHR 95% CI P-value EHR 95% CI P-value
Deprivation
Affluent 1.00 0.391 1.00 0.707
2 1.06 (0.86–1.30) 1.02 (0.83–1.26)
3 1.12 (0.91–1.36) 1.11 (0.91–1.35)
4 1.20 (0.98–1.46) 1.14 (0.93–1.39)
Deprived 1.17 (0.95–1.44) 1.08 (0.88–1.33)
Age at randomisation
o55 Years 1.00 0.005
55–65 Years 1.25 (1.08–1.45)
465 Years 1.25 (1.06–1.48)
Period of randomisation
1991–1995 1.00 0.024
1996–1999 0.85 (0.74–0.98)
FIGO stage at diagnosis
Stage I 1.00 o0.001
Stage II 1.12 (0.76–1.65)
Stage III 2.92 (2.13–4.00)
Stage IV 4.30 (3.07–6.01)
Deviance¼1047 Deviance¼ 861
Residual degrees of freedom¼884 Residual degrees of freedom¼878
Abbreviations: CI¼ confidence interval; EHR¼ excess hazard ratio; FIGO¼ International Federation of Gynecology and Obstetrics; ICON¼ International Collaborative Ovarian Neoplasm.
Women recruited to ICON2 and ICON3 trials of ovarian cancer during 1991–1998 are shown.
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deprivation among women with ovarian cancer occur within 5
years of diagnosis. Ovarian cancer is often diagnosed at an
advanced stage; therefore, many women will not receive treatment
of curative intent, but palliative treatment such as second-line
chemotherapy or surgery for recurrent or progressive disease may
be less available to deprived women. The reduction in the
deprivation gap in survival by 5 years after diagnosis may therefore
reflect the inevitable course of disease. The absence of a deprivation
gap in survival at 5 years and more may also be attributable to
better access to specialist treatment for more affluent women
(Kitchener, 2008). No socioeconomic difference in 5-year survival
was seen in a study in Scotland (Shack et al, 2007).
Relative survival at 1 year among women with ovarian cancer in
the ICON trials was 12–17% higher than among women in the
general population, but 5- and 10-year survival were lower.
Survival among patients recruited to clinical trials is often higher
than for the generality of cancer patients because trial patients
receive at least the best available treatment, adherence to protocol
is strict and they are often younger than average, as was the case
here. The lower long-term survival among women in the ICON
trials therefore merits consideration. It is probably attributable to
several selection factors: (a) FIGO stage III or IV disease was more
common among women in the ICON trials (80%) than in the
general population (60–70%); (b) women with ovarian tumours of
borderline malignancy were not included in the trials, and these
tumours generally have a good long-term prognosis; (c) women in
the trials were fit enough to receive chemotherapy, and thus more
likely to survive at least 1 year after diagnosis, but without longer-
term benefit: median survival was 33 months in ICON2 and 36
months in ICON3. In short, women recruited to the ICON trials
were not only younger than is typical for all women with ovarian
cancer (median age 58 vs 65 years), but probably somewhat fitter,
despite having more advanced disease.
The principal strength of this study is the follow-up of all the
women for their vital status, many years after closure of the ICON
trials in 1998. This allowed survival analysis up to 2007, by which
time most of the women had died. Although follow-up in the trials
was from the date of randomisation, not from the date of diagnosis,
as in population survival studies, the median difference between
diagnosis and randomisation was just 25 days. These were large
trials; however, they were not designed to examine survival in five
categories of socioeconomic deprivation. We can rule out a large
deprivation gap in survival; however, statistical power to detect
more modest effects of deprivation is limited. No information on
stage was available in the population-based data to enable the same
type of adjustment carried out with the trial data. Nonetheless, a
generalised linear model that includes follow-up time, deprivation
and age showed that deprivation was significantly related to
survival (global likelihood ratio test P-value o0.001; results not
shown).
The main limitation of this study is statistical power.
Examination of survival differences by socioeconomic status was
not part of the original trial designs; the trials would need to have
been several times larger had that been so. We deliberately selected
the largest available MRC trials of treatment for ovarian cancer.
There are only moderate numbers of events (deaths) in each
deprivation category. This study represents opportunistic second-
ary use of high-quality data from well-conducted randomised trials
to examine a hypothesis about one possible cause of socioeconomic
inequalities in cancer survival in the general population.
The ICON2 and ICON3 trials concerned primary treatment.
The women in the trials were not a random sample of all women
with ovarian cancer. They differed from all women with ovarian
cancer in England and Wales in terms of age and stage of disease at
diagnosis. These patterns help to explain the differences in overall
survival between women with ovarian cancer in the trial and those
in the general population. By contrast, the socioeconomic status of
the women in the trials was remarkably similar to that of all
women with ovarian cancer in England and Wales.
The women in these two well-conducted ovarian cancer trials
were recruited with similar levels of disease, they were given
treatment of equally efficacy and their socioeconomic status was
not overtly known or recorded during the trials.
The absence of a socioeconomic gradient in short-term survival
is therefore important. It strongly suggests that equal treatment of
cancer patients can yield equal outcome, regardless of socio-
economic status. Given the persistent socioeconomic inequalities in
survival among women with ovarian cancer in the general
population, and among cancer patients more generally (Coleman
et al, 1999; Rachet et al, 2010), that seems an observation worth
making.
CONCLUSION
The findings showed no statistically significant association between
socioeconomic deprivation and relative survival from ovarian
cancer among women in two clinical trials whose socioeconomic
status was not known at the time of the trial, and who were given
treatments that, as it transpired, were of equal efficacy.
In other words, the trial produced evidence that equal treatment
yields equal outcome, regardless of socioeconomic status.
The significant deprivation gap in 1-year relative survival seen
among women with ovarian cancer in the general population may
therefore be attributable to socioeconomic differences in access to
optimal treatment.
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CENTRES AND CLINICIANS PARTICIPATING IN ICON2
AND ICON3 IN ENGLAND AND WALES: FOR A FULL LIST
OF INVESTIGATORS, SEE PARMAR et al (1998, 2002)
Aberystwyth: Bronglais General Hospital (AT Axford); Bangor:
Ysbyty Gwynedd (N Stuart); Birmingham Heartlands Hospital
(I Fernando); Birmingham Women’s Hospital (KK Chan, C Poole,
ST Kehoe); Birmingham: City Hospital (C Poole, D Spooner);
Birmingham: Queen Elizabeth Hospital (A Chetiyawardana,
I Fernando, J Mould, C Poole, D Spooner); Bradford Royal
Infirmary (C Bradley); Bristol Oncology Centre (A Brewster,
S Falk, J Graham); Cambridge: Addenbrooke’s Hospital
(R Allerton, HM Earl, R Osborne, C Wilson, R Hawkins); Cardiff:
Velindre Hospital (M Adams); Coventry: Walsgrave Hospital
(M Hocking, C Irwin, A Stockdale); Cumberland Infirmary
(J Nicoll); Derby City Hospital (IV Scott); Derbyshire Royal
Infirmary (D Guthrie); Essex County Hospital (P Murray, S Tahir);
Exeter: Royal Devon and Exeter Hospital (A Hong); Gateshead:
Queen Elizabeth Hospital (N Bailey, J Bozzino, J Monaghan,
A Lopes); Guildford: St Luke’s Cancer Centre (A Folkes, R Laing,
C Topham); Huddersfield Royal Infirmary (J Joffe); Ipswich
Hospital (J Morgan); Jersey General Hospital (S Hima,
C Williams); Lancaster: Royal Lancaster Infirmary (MMcIllmurray);
Leeds General Infirmary (E Buxton, KR Peel); Leeds: St James’s
University Hospital (T Perren); Leicester Royal Infirmary
(S Khanna, F Madden); Lincoln: County Hospital (E Murray);
Liverpool: Royal Liverpool Hospital (J A Green, P Hendy-Ibbs);
London: Hammersmith Hospital (H Thomas, C Vernon); London:
Middlesex Hospital (A Cassoni, JA Lederman, RL Souhami);
London: North Middlesex Hospital (N Davidson, S Davies, S Karp);
No socioeconomic inequalities in ovarian cancer survival BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.303 595
London: Charing Cross Hospital (G Rustin, MJ Seckl, R Coombes);
London: Chelsea and Westminster Hospital (R Phillips); London:
Guy’s Hospital (PG Harper); London: King’s College Hospital
(F Calman, HJ Dobbs); London: Royal Free Hospital (A Jones,
J Ledermann); London: Royal London Hospital (C Gallagher);
London: Royal Marsden Hospital (M Gore); London: St Bartholomew’s
Hospital (A Clayton-Jolly, C Gallagher, M Slevin); London:
St George’s (F Lofts, J Mansi); London: St Mary’s Hospital
(C Coulter); London: St Thomas’s Hospital (R Beaney, F Calman);
London: Whittington Hospital (JA Ledermann); Maidstone
Hospital (J Summers, M O’Brien); Manchester: Christie Hospital
(D Crowther, G Jayson, J Radford, R Welch, P Wilkinson);
Manchester: Tameside General Hospital (W O Goldthorp,
J K Roberts); Middlesbrough: South Cleveland Hospital (R Garry);
Northwood: Mount Vernon Hospital (P Hoskin, G Rustin);
Newcastle General Hospital (J Bozzino, H Calvert); Northampton
General Hospital (D Levy, R Matthew, M Paterson, J Stewart);
Nottingham City Hospital (S Chan); Oxford: Churchill Hospital
(T Ganesan, B Lavery); Oxford: Manor Hospital (A Chetiyawardana);
Peterborough District General Hospital (LT Tan); Plymouth
General (F Daniel); Poole General Hospital (N Cowley, R Osborne,
CJ Williams); Romford: Oldchurch Hospital (M Quigley); Royal
Shrewsbury Hospital (S Awwad, R Gopal); Salisbury District
(T Iveson); Sheffield: Weston Park Hospital (R Coleman,
DJ Radstone, MJ Whipp); Southampton General Hospital
(JMA Whitehouse, CJ Williams); Southampton: Royal South
Hants Hospital (V Hall, TJ Iveson, P Simmonds, JMA Whitehouse,
CJ Williams); Southend General Hospital (A Lamont, A Robinson,
CW Trask); Stoke City General Hospital (AW Clubb); Stoke
Mandeville Hospital (N Warner); Stoke: North Staffordshire Royal
Infirmary (F Adab, CWE Redman, JE Scoble); Sussex Oncology
Centre (D Murrell, G Newman, M Wilkins); Windsor: Princess
Margaret Hospital (D Cole, J Cullimore); Wirral: Clatterbridge
Centre for Oncology (JA Green); Wolverhampton: New Cross
Hospital (R Allerton); Wycombe General Hospital (B Lavery).
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